Seeking Alpha

Synergy Pharmaceuticals commences pivotal plecanatide CIC trial

  • Synergy Pharmaceuticals (SGYP +2.5%) initiates a Phase 3 pivotal trial of plecanatide in CIC. Primary endpoint: Proportion of patients who are overall responders.
  • The company is confident the GC-C agonist is "best-in-class."
  • Top-line data from an ongoing Phase 2b study of plecanatide in IBS-C is due in Q1 2014. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector